The invention relates to the field of medicine formulas and specifically relates to avicennia marina leaf powder for hypertrophic gonarthritis. The avicennia marina leaf powder is characterized by comprising the following raw materials in percentage by weight: 15-18% of glandular parathelypteris, 10-13% of root of Yunna cowparsnip, 7-10% of fortune's drynaria rhizome, 7-9% of garden balsam stem, 6-9% of eucommica leaf, 1-2% of dragon's blood, 1-2% of manchurian wildginger, 4-7% of earthworm, 5-8% of Chinese taxillus twig, 2-5% of towel gourd vegetable sponge, 3-5% of cassia bark, 4-6% of doubleteeth pubescent angilica root, 4-6% of pangolin scales, 5-7% of common floweringquince fruit, 1-3% of natural indigo and 3-6% of liquorice root, and the 16 active pharmaceutical ingredients are dried, ground into fine powder and screened by a 100-mesh screen. The avicennia marina leaf powder disclosed by the invention has the beneficial effects of low cost, obvious effects particularly against joint swelling, joint effusion, limited activity and other symptoms in hypertrophic arthritis, no toxicity, no side effects and effects of activating qi-flowing, removing blood stasis, activating meridians and collaterals, dispelling pathogenic wind, eliminating dampness, penetrating bones to expel pathogenic factors from muscles, alleviating convulsion and reliving pain.